A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Omecantiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction.
Phase III. Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients with Community –Acquired Pneumonia.
Phase III. Strategies using XXXXX to avoid transfusions in chronic kidney disease. (START-CKD).
Phase III. A multinational, randomized, double-blind, placebo-controlled trial to evaluate the effect of XXXXX 90 mg twice a day on the incidence of cardiovascular death, myocardial infarction or stroke in patients with type II diabetes mellitus. THEMIS.
Phase IV. A Multicenter, International, Randomized, Parallel group, Double Blind, Placebo-Controlled Cardiovascular Safety & Renal Microvascular outcome with XXXXXXX, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk. CARMELINA.
Phase IV. A Randomized, Placebo- Controlled, Double- Blind, Parallel Group Study to assess the Safety and Efficacy of XXX delivered via HandiHaler in COPD Subjects recovering from Hospitalization for an acute exacerbation. (Hospital Discharge Study 1).
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate Cardiovascular Outcomes of XXX, 50 mg in addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for cardiovascular Events. TAK-875_306.
Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of XXX in Subjects with Acute Otitis Externa.
Phase II/III. Global Registry on Long-Term Oral Anti-thrombotic treatment in patients with Atrial Fibrillation Phase II and III. GLORIA.
Phase I/II. A Study in Japan and Ex-Japan to Characterized the Pharmacokinetic and Pharmacodynamic Response to Orteronel (XXX-700) in Chemotherapy Naïve patients with Castration-Resistant Prostate Cancer
Phase III. An Open Label, Randomized, Comparison of the Immunogenicity and Safety of Human Insulin Basal Bolus Regimen (XXXX 70/30) with the Sponsor Yeast based Human Insulin Basal Bolus Regimens, marketed in the United States (XXXX 70/30) in Type I Diabetes
Phase IV. An Open Label study to evaluate the safety. Tolerability and pharmacokinetics of XXXX in combination with other antiretrovirals (ARVs) in antiretroviral treatment-experienced HIV-1 infected subjects. TIBOTEC.
Phase III. Cardiovascular outcomes Study to evaluate the potential of XXXX to reduce cardiovascular risk in patients with a recent Acute Coronary Syndrome (ACS) event and type 2 diabetes mellitus (T2DM) ALECARDIO.
Phase III. An Open Label, 52 Week Study to Assess the Long-Term Safety of XXXX in Opioid-Induced Constipation (OIC) in Patients with Non-Cancer-Related Pain. KODIAC08.
Phase III. An Open Label, 52 Week Study to Assess the Long-Term Safety of XXXX in Opioid-Induced Constipation (OIC) in Patients with Cancer-Related Pain. KODIAC06.
Self-Medication in Cuba, Clinical Pharmacology. Dr. Alberto Zamora, Dr. Leandro Lopez, Dr. Luis A. Martinez
Diabetes. Diagnostic and treatment in the primary care. Dr. Luis A. Martinez., Dr. Damara Malo de Molina., Dr. Xohan Lafont
STD’s in adolescent patients, major risk factors, prevalence and social impact. Dr. Luis A. Martinez., Dr. Maritza Novas, Dr. Alberto Gomez